Omeros (OMER) Change in Accured Expenses (2010 - 2026)
Omeros (OMER) posted Change in Accured Expenses of -$979000.0 for Q1 2026, up 44.15% sequentially from -$1.8 million in Q4 2025, and up 80.58% YoY from -$542132.7 in Q1 2025.
Analysis
Omeros (OMER) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Omeros has reported Change in Accured Expenses for 17 years, with the latest figure at -$979000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 80.58% year-over-year to -$979000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 263.61% YoY) and the FY2025 annual result came in at $4.6 million, up 187.46% from the prior year.
- Change in Accured Expenses rose to -$979000.0 in Q1 2026 per OMER's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $8.2 million in Q2 2025 and troughed at -$15.7 million in Q1 2022.
- A 5-year average of -$448176.5 and a median of $879000.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 781.72% in 2024, then soared 1336.43% in 2025.
- Over 5 years, Change in Accured Expenses stood at $879000.0 in 2022, then advanced by 7.05% to $941000.0 in 2023, then soared by 544.63% to $6.1 million in 2024, then sank by 128.9% to -$1.8 million in 2025, then soared by 44.15% to -$979000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$979000.0, -$1.8 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 2.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22 Mn |
| Mar 31, 2026 | -979,000.00 |
| Dec 31, 2025 | -1.75 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 6.07 Mn |
| Sep 30, 2024 | -5.64 Mn |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | 941,000.00 |
| Sep 30, 2023 | 982,000.00 |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 733,000.00 |
| Dec 31, 2022 | 879,000.00 |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 3.02 Mn |
| Mar 31, 2022 | -15.67 Mn |
| Dec 31, 2021 | 9.84 Mn |
| Sep 30, 2021 | -5.07 Mn |